Pre-Open Stock Movers 11/30: (CPIX) (IMGN) (VIR) Higher; (JKS) (LIZI) (SEDG) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
MEI Pharma (MEIP) Prices 17.5M Share Offering at $2.60/sh
December 2, 2021 5:56 AM ESTMEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has priced the underwritten public offering of 17,500,000 shares of its common stock at $2.60 per share for total gross proceeds (before underwriting discount and commissions and estimated expenses) of $45,500,000. In connection with the offering, the Company granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of common stock offered in the public offering. The offering is expected to close on December 6, 2021, subject to the satisfaction of customary closing... More
Immunogen (IMGN) Prices Upsized 11.64M Share Offering at $6.60/sh
December 2, 2021 5:52 AM ESTImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 11,636,364 shares of its common stock at a price of $6.60 per share, before underwriting discounts and commissions, and to certain... More
Vir Biotechnology Inc. (VIR) and GlaxoSmithKline's (GSK) Sotrovimab Retains Activity Against Key Omicron Mutations, per Preclinical Data
December 2, 2021 5:49 AM ESTGlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations1 of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated... More
JinkoSolar (JKS) Announces 2 GW Distribution Contract for DG with Aldo Solar for 2022
December 2, 2021 5:46 AM ESTJinkoSolar Holding Co., Ltd. (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that its principal operating subsidiary, Jinko Solar Co., Ltd. and Aldo Solar, which stands out as the largest distributor of solar energy solutions in Brazil with 31% market share, reinforce their partnership for 2022 with the signing of the largest distribution agreement for Distributed Generation ever signed by Jinko Solar Co., Ltd. outside China.
Under the agreement, approximately 4 million photovoltaic modules will be distributed, equivalent to 2 GW of installed power. The contract assures... More
Krystal Biotech (KRYS) Prices 2.67M Share Offering at $75/sh
December 1, 2021 5:25 AM ESTKrystal Biotech, Inc. (NASDAQ: KRYS) the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Companys common stock offered in the public offering. The gross proceeds to the Company from this offering are expected to be approximately $200 million, before deducting the underwriting discounts and commissions and other... More

